Please Wait.....

Report

Global Branded Generics Market

Market Report I 2025-11-01 I 350 Pages I Data Bridge Market Research

Global branded generics market is expected to reach USD 403.37 billion by 2032 from USD 264.77 billion in 2024, growing at a substantial CAGR of 5.5% in the forecast period of 2025 to 2032.
Market Segmentation:
Global Branded Generics Market, By Drug Class (Anti-Hypertensive, Hormones, Antimetabolites, Lipid Lowering Drugs, Anti-Epileptics, Alkylating Agents, Anti-Depressants, Anti-Psychotics, Others), Application (Cardiovascular Diseases, Pain Management and Anti-inflammatory, Oncology, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology, Others), Route of Administration (Oral, Injectable, Topical Administration, Others), Product Type (Value-Added Branded Generics, Trade Named Generics), Patient Demographics (Adult, Geriatric, Pediatric), End User (Hospitals, Clinics, Homecare, Academic & Research Institutes, Others) Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Direct Tenders, Others) Country (North America, Europe, Asia-Pacific, South America and Middle East and Africa). These regions are further segmented into major countries such as the U.S., Canada, Mexico, Germany, France, U.K., Hungary, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest Of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest Of Asia-Pacific, Brazil, Argentina, Peru, Rest Of South America, Saudi Arabia, South Africa, UAE, Egypt, Kuwait, Israel, Rest Of Middle East and Africa).
Overview of the Global Branded generics Market are:

Driver

- Patent expirations of blockbuster drugs
- Rising prevalence of chronic diseases
- Cost-effective alternative to innovator drugs
- Simplified approval pathways for branded generics

Restrain
- Patent litigation and intellectual property risks
- Counterfeit and substandard drugs
Opportunity

- Expansion of branded generic drug in emerging markets
- Patent cliff of major drugs
- Expansion into specialty and complex generics

Market Players:

The key market players for global branded generics market are listed below:

- Teva Pharmaceutical Industries Ltd. (Israel)
- Viatris Inc. (U.S.)
- Sandoz Group AG (Switzerland)
- Dr. Reddy's Laboratories Ltd. (India)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Cipla Pharmaceuticals (India)
- Fresenius Kabi (Germany)
- Abbott (U.S.)
- Glenmark Pharmaceuticals (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Lupin Pharmaceuticals (India)
- Emcure Pharmaceuticals (India)
- Bausch Health Companies Inc. (Canada)
- Mankind Pharma (India)
- Jubilant Pharma (India)
- Natco Pharma (India)
- ARISTO Pharmaceuticals Private Limited (India)
- Biocon Limited (India)
- Torrent Pharmaceuticals Ltd. (India)
- Endo, Inc. (U.S.)
- Alembic Pharmaceuticals Limited (India)
- SAGENT Pharmaceuticals (U.S.)
- Panacea Biotec (India)

TABLE OF CONTENTS
1 INTRODUCTION 197
1.1 OBJECTIVES OF THE STUDY 197
1.2 MARKET DEFINITION 197
1.3 OVERVIEW OF GLOBAL BRANDED GENERICS MARKET 197
1.4 LIMITATIONS 200
1.5 MARKETS COVERED 201
2 MARKET SEGMENTATION 209
2.1 MARKETS COVERED 209
2.2 GEOGRAPHICAL SCOPE 210
2.3 YEARS CONSIDERED FOR THE STUDY 211
2.4 CURRENCY AND PRICING 211
2.5 DBMR TRIPOD DATA VALIDATION MODEL 212
2.6 MULTIVARIATE MODELLING 215
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 216
2.8 DBMR MARKET POSITION GRID 218
2.9 MARKET END USER COVERAGE GRID 219
2.10 SECONDARY SOURCES 220
2.11 ASSUMPTIONS 221
3 EXECUTIVE SUMMARY 222
4 PREMIUM INSIGHTS 229
4.1 PORTER'S FIVE FORCES ANALYSIS 232
4.2 BRAND OUTLOOK 233
4.2.1 PRODUCT VS BRAND OVERVIEW 234
4.2.1.1 PRODUCT OVERVIEW 234
4.2.1.2 BRAND OVERVIEW 235
4.3 CONSUMER BUYING BEHAVIOUR - GLOBAL BRANDED GENERICS MARKET 236
4.4 INNOVATION TRACKER AND STRATEGIC ANALYSIS 238
4.4.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS 238
4.4.1.1 JOINT VENTURES 238
4.4.1.2 MERGERS AND ACQUISITIONS 238
4.4.1.3 LICENSING AND PARTNERSHIP 239
4.4.1.4 TECHNOLOGY COLLABORATIONS 240
4.4.1.5 STRATEGIC DIVESTMENTS 240
4.4.2 NUMBER OF PRODUCTS IN DEVELOPMENT 241
4.4.3 STAGE OF DEVELOPMENT 241
4.4.4 TIMELINES AND MILESTONES 241
4.4.5 INNOVATION STRATEGIES AND METHODOLOGIES 241
4.4.6 RISK ASSESSMENT AND MITIGATION 242
4.4.7 FUTURE OUTLOOK 242
4.5 PATENT ANALYSIS - GLOBAL BRANDED GENERICS MARKET 243
4.5.1 PATENT QUALITY AND STRENGTH 243
4.5.2 PATENT FAMILIES 243
4.5.3 LICENSING AND COLLABORATIONS 244
4.5.4 REGIONAL PATENT LANDSCAPE 244
4.5.5 IP STRATEGY AND MANAGEMENT 245
4.6 PRICING ANALYSIS 246
4.7 VALUE CHAIN ANALYSIS 248
4.7.1 OVERVIEW 248
4.7.2 RAW MATERIAL SUPPLY 248
4.7.3 COMPONENT MANUFACTURING AND PROCESSING 248
4.7.4 EQUIPMENT AND TECHNOLOGY PROVIDERS 249
4.7.5 DISTRIBUTION AND LOGISTICS 249
4.7.6 END-USERS (BRANDS & INDUSTRY SECTORS) 249
4.7.7 CONCLUSION 250
5 REGULATION COVERAGE 251
5.1 REGULATION COVERAGE (NORTH AMERICA) 251
5.2 REGULATION COVERAGE (SOUTH AMERICA) 254
5.3 REGULATION COVERAGE (EUROPE) 257
5.4 REGULATION COVERAGE (MIDDLE EAST & AFRICA) 260
5.5 REGULATION COVERAGE (ASIA-PACIFIC) 263
5.6 SUPPLY CHAIN ANALYSIS OF GLOBAL BRANDED GENERICS MARKET 266
5.6.1 OVERVIEW 266
5.6.2 LOGISTIC COST SCENARIO 266
5.6.3 IMPORTANCE OF LOGISTICS SERVICE PROVIDERS 266
5.6.4 CONCLUSION 266
5.7 TECHNOLOGICAL ADVANCEMENTS- GLOBAL BRANDED GENERICS MARKET 267
5.7.1 ADVANCED FORMULATION TECHNOLOGIES 267
5.7.2 CONTINUOUS MANUFACTURING AND PROCESS OPTIMIZATION 267
5.7.3 ANTI-COUNTERFEITING AND SMART PACKAGING TECHNOLOGIES 267
5.7.4 MODIFIED DRUG DELIVERY SYSTEMS 268
5.7.5 DIGITAL TRANSFORMATION AND E-PRESCRIPTION INTEGRATION 268
5.7.6 ADVANCED ANALYTICAL AND QUALITY ASSURANCE TOOLS 268
5.7.7 PERSONALIZED GENERIC THERAPY DEVELOPMENT 268
5.7.8 SUSTAINABILITY AND ECO-FRIENDLY MANUFACTURING 269
6 MARKET OVERVIEW 270
6.1 DRIVERS 272
6.1.1 PATENT EXPIRATIONS OF BLOCKBUSTER DRUGS 272
6.1.2 RISING PREVALENCE OF CHRONIC DISEASES 273
6.1.3 COST-EFFECTIVE ALTERNATIVE TO INNOVATOR DRUGS 274
6.1.4 SIMPLIFIED APPROVAL PATHWAYS FOR BRANDED GENERICS 275
6.2 RESTRAINS 276
6.2.1 PATENT LITIGATION AND INTELLECTUAL PROPERTY RISKS 276
6.2.2 COUNTERFEIT AND SUBSTANDARD DRUGS 277
6.3 OPPORTUNITIES 278
6.3.1 EXPANSION OF BRANDED GENERIC DRUG IN EMERGING MARKETS 278
6.3.2 PATENT CLIFF OF MAJOR DRUGS 279
6.3.3 EXPANSION INTO SPECIALTY AND COMPLEX GENERICS 280
6.4 CHALLENGES 281
6.4.1 INTENSE PRICE PRESSURE AMONG COMPETITORS 281
6.4.2 QUALITY PERCEPTION & PHYSICIAN/PATIENT TRUST IN BRANDED GENERIC DRUG 282
7 GLOBAL BRANDED GENERIC MARKET, BY DRUG CLASS 283
7.1 OVERVIEW 284
7.2 ANTI-HYPERTENSIVE 287
7.2.1 DIURETICS 289
7.2.2 CE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) 289
7.2.3 ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) 290
7.2.4 BETA BLOCKERS (BBS) 290
7.2.5 CALCIUM CHANNEL BLOCKERS (CCBS) 291
7.2.6 DIRECT VASODILATORS 291
7.2.7 ALPHA-1 BLOCKERS 292
7.2.8 CENTRAL ALPHA-2 AGONISTS 292
7.2.9 HORMONES 293
7.2.10 STEROID HORMONES 294
7.2.11 SEX HORMONES 294
7.2.12 ESTROGENS 295
7.2.13 PROGESTOGENS 295
7.2.14 ANDROGENS 296
7.2.15 THYROID HORMONES 296
7.2.16 OTHER HORMONES 297
7.3 ANTIMETABOLITES 297
7.3.1 PURINE ANALOGUES 298
7.3.2 PYRIMIDINE ANALOGUES 299
7.3.3 FOLATE ANTAGONISTS 299
7.4 LIPID LOWERING DRUGS 300
7.4.1 STATINS (HMG-COA REDUCTASE INHIBITORS) 301
7.4.2 COMBINATION PRODUCTS AND OTHER AGENTS 302
7.4.3 FIBRATES 302
7.4.4 BILE ACID SEQUESTRANTS 303
7.4.5 PCSK9 INHIBITORS 303
7.5 ANTI-EPILEPTICS 304
7.6 ALKYLATING AGENTS 305
7.6.1 NITROGEN MUSTARDS 307
7.6.2 NITROSOUREAS 307
7.6.3 ALKYL SULFONATES 308
7.6.4 TRIAZENES 308
7.6.5 ETHYLENIMINES 309
7.7 ANTI-DEPRESSANTS 309
7.7.1 SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) 311
7.7.2 SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) 312
7.7.3 TRICYCLIC ANTIDEPRESSANTS (TCAS) 313
7.7.4 ATYPICAL ANTIDEPRESSANTS 314
7.7.5 MONOAMINE OXIDASE INHIBITORS (MAOIS) 314
7.7.6 NMDA RECEPTOR ANTAGONISTS 315
7.8 ANTI-PSYCHOTICS 315
7.8.1 SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS 317
7.8.2 FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS 318
7.8.3 PHENOTHIAZINES 319
7.8.4 THIOXANTHENES 319
7.8.5 NEXT-GENERATION ANTIPSYCHOTICS 320
7.9 OTHERS 320
8 GLOBAL BRANDED GENERICS MARKET, BY APPLICATION 321
8.1 OVERVIEW 322
8.2 CARDIOVASCULAR DISEASES 325
8.3 PAIN MANAGEMENT AND ANTI-INFLAMMATORY 326
8.4 ONCOLOGY 327
8.5 DIABETES 329
8.6 NEUROLOGY 330
8.7 GASTROINTESTINAL DISEASES 331
8.8 DERMATOLOGY 332
8.9 OTHERS 333
9 GLOBAL BRANDED GENERIC MARKET, BY ROUTE OF ADMINISTRATION 335
9.1 OVERVIEW 336
9.2 ORAL 339
9.3 INJECTABLEA 340
9.4 TOPICAL ADMINISTRATION 341
9.5 OTHERS 343
10 GLOBAL BRANDED GENERICS MARKET, BY PRODUCT TYPE 344
10.1 OVERVIEW 345
10.2 VALUE-ADDED BRANDED GENERICS 348
10.3 TRADE NAMED GENERICS 349
11 GLOBAL BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS 350
11.1 OVERVIEW 351
11.2 ADULT 354
11.3 GERIATRIC 355
11.4 PEDIATRIC 356
12 GLOBAL BRANDED GENERICS MARKET, BY END USER 357
12.1 OVERVIEW 358
12.2 HOSPITALS 361
12.3 CLINICS 361
12.4 HOMECARE 362
12.5 ACADEMIC & RESEARCH INSTITUTES 363
12.6 OTHERS 363
13 GLOBAL BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL 364
13.1 OVERVIEW 365
13.2 RETAIL PHARMACIES 368
13.3 HOSPITAL PHARMACIES 369
13.4 DIRECT TENDERS 370
13.5 OTHERS 371
14 GLOBAL SHIP REPAIR AND MAINTENANCE SERVICES MARKET, BY REGION 372
14.1 OVERVIEW 373
14.2 ASIA-PACIFIC 377
14.2.1 CHINA 404
14.2.2 INDIA 427
14.2.3 JAPAN 450
14.2.4 SOUTH KOREA 472
14.2.5 AUSTRALIA 494
14.2.6 THAILAND 515
14.2.1 INDONESIA 537
14.2.2 SINGAPORE 558
14.2.3 MALAYSIA 579
14.2.4 TAIWAN 600
14.2.5 PHILIPPINES 620
14.2.6 HONG KONG 640
14.2.7 NEW ZEALAND 661
14.2.8 REST OF ASIA-PACIFIC 681
14.3 EUROPE 682
14.3.1 GERMANY 708
14.3.2 UNITED KINGDOM 730
14.3.3 ITALY 752
14.3.4 FRANCE 774
14.3.5 SPAIN 795
14.3.6 TURKEY 816
14.3.7 RUSSIA 837
14.3.8 SWITZERLAND 858
14.3.9 NETHERLANDS 879
14.3.10 BELGIUM 900
14.3.11 SWEDEN 920
14.3.12 DENMARK 941
14.3.13 NORWAY 961
14.3.14 FINLAND 981
14.3.15 REST OF EUROPE 1001
14.4 NORTH AMERICA 1002
14.4.1 U.S. 1027
14.4.2 CANADA 1050
14.4.3 MEXICO 1072
14.5 SOUTH AMERICA 1093
14.5.1 BRAZIL 1119
14.5.2 ARGENTINA 1141
14.5.3 COLOMBIA 1161
14.5.4 CHILE 1181
14.5.5 PERU 1201
14.5.6 ECUADOR 1220
14.5.7 URUGUAY 1239
14.5.8 VENEZUELA 1258
14.5.9 BOLIVIA 1278
14.5.10 PARAGUAY 1298
14.5.11 REST OF SOUTH AMERICA 1317
14.6 MIDDLE EAST AND AFRICA 1318
14.6.1 SAUDI ARABIA 1343
14.6.2 UNITED ARAB EMIRATES 1364
14.6.3 EGYPT 1384
14.6.4 SOUTH AFRICA 1404
14.6.5 ISRAEL 1425
14.6.6 KUWAIT 1445
14.6.7 BAHRAIN 1465
14.6.8 QATAR 1485
14.6.9 OMAN 1504
14.6.10 REST OF MIDDLE EAST AND AFRICA 1523
15 GLOBAL BRANDED GENERICS MARKET: COMPANY LANDSCAPE 1524
15.1 MANUFACTURER COMPANY SHARE ANALYSIS: GLOBAL 1524
15.2 COMPANY SHARE ANALYSIS: EUROPE 1525
15.3 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 1526
15.4 COMPANY SHARE ANALYSIS: NORTH AMERICA 1527
16 SWOT ANALYSIS 1528
17 COMPANY PROFILE 1529
17.1 TEVA PHARMACEUTICAL INDUSTRIES LTD. 1529
17.1.1 COMPANY SNAPSHOT 1529
17.1.2 REVENUE ANALYSIS 1530
17.1.3 COMPANY SHARE ANALYSIS 1530
17.1.4 PRODUCT PORTFOLIO 1531
17.1.5 RECENT DEVELOPMENT 1533
17.2 VIATRIS INC. 1535
17.2.1 COMPANY SNAPSHOT 1535
17.2.2 REVENUE ANALYSIS 1536
17.2.3 COMPANY SHARE ANALYSIS 1536
17.2.4 PRODUCT PORTFOLIO 1537
17.2.5 RECENT DEVELOPMENTS 1541
17.3 SANDOZ GROUP AG 1543
17.3.1 COMPANY SNAPSHOT 1543
17.3.2 REVENUE ANALYSIS 1543
17.3.3 COMPANY SHARE ANALYSIS 1544
17.3.4 PRODUCT PORTFOLIO 1544
17.3.5 RECENT DEVELOPMENTS 1547
17.4 DR.REDDY�S LABORATORIES LTD. 1549
17.4.1 COMPANY SNAPSHOT 1549
17.4.2 REVENUE ANALYSIS 1549
17.4.3 COMPANY SHARE ANALYSIS 1550
17.4.4 PRODUCT PORTFOLIO 1550
17.4.5 RECENT DEVELOPMENTS 1556
17.5 SUN PHARMACEUTICAL INDUSTRIES LTD. 1558
17.5.1 COMPANY SNAPSHOT 1558
17.5.2 REVENUE ANALYSIS 1559
17.5.3 COMPANY SHARE ANALYSIS 1559
17.5.4 PRODUCT PORTFOLIO 1560
17.5.5 RECENT DEVELOPMENTS 1565
17.6 ABBOTT 1567
17.6.1 COMPANY SNAPSHOT 1567
17.6.2 REVENUE ANALYSIS 1567
17.6.3 PRODUCT PORTFOLIO 1568
17.6.4 RECENT DEVELOPMENTS 1569
17.7 ALEMBIC PHARMACEUTICALS LIMITED 1570
17.7.1 COMPANY SNAPSHOT 1570
17.7.2 REVENUE ANALYSIS 1571
17.7.3 PRODUCT PORTFOLIO 1571
17.7.4 RECENT DEVELOPMENT 1573
17.8 AMNEAL PHARMACEUTICALS LLC. 1574
17.8.1 COMPANY SNAPSHOT 1574
17.8.2 REVENUE ANALYSIS 1574
17.8.3 PRODUCT PORTFOLIO 1575
17.8.4 RECENT DEVELOPMENT 1576
17.9 ARISTO PHARMACEUTICALS PRIVATE LIMITED 1577
17.9.1 COMPANY SNAPSHOT 1577
17.9.2 PRODUCT PORTFOLIO 1577
17.9.3 RECENT DEVELOPMENT 1578
17.10 ASPEN HOLDINGS 1579
17.10.1 COMPANY SNAPSHOT 1579
17.10.2 REVENUE ANALYSIS 1579
17.10.3 PRODUCT PORTFOLIO 1580
17.10.4 RECENT DEVELOPMENT 1581
17.11 AUROBINDO PHARMA USA (SUBSIDIARY OF AUROBINDO PHARMA LIMITED) 1582
17.11.1 COMPANY SNAPSHOT 1582
17.11.2 REVENUE ANALYSIS 1583
17.11.3 PRODUCT PORTFOLIO 1583
17.11.4 RECENT DEVELOPMENTS 1586
17.12 BAUSCH HEALTH COMPANIES INC. 1589
17.12.1 COMPANY SNAPSHOT 1589
17.12.2 REVENUE ANALYSIS 1589
17.12.3 PRODUCT PORTFOLIO 1590
17.12.4 RECENT DEVELOPMENT 1591
17.13 BIOCON. 1592
17.13.1 COMPANY SNAPSHOT 1592
17.13.2 REVENUE ANALYSIS 1592
17.13.3 PRODUCT PORTFOLIO 1593
17.13.4 RECENT DEVELOPMENTS 1594
17.14 CIPLA 1595
17.14.1 COMPANY SNAPSHOT 1595
17.14.2 REVENUE ANALYSIS 1595
17.14.3 PRODUCT PORTFOLIO 1596
17.14.4 RECENT DEVELOPMENTS 1599
17.15 EMCURE PHARMACEUTICALS LIMITED 1601
17.15.1 COMPANY SNAPSHOT 1601
17.15.2 REVENUE ANALYSIS 1602
17.15.3 PRODUCT PORTFOLIO 1602
17.15.4 RECENT DEVELOPMENTS 1605
17.16 ENDO, INC. 1607
17.16.1 COMPANY SNAPSHOT 1607
17.16.2 REVENUE ANALYSIS 1608
17.16.3 PRODUCT PORTFOLIO 1608
17.16.4 RECENT DEVELOPMENT 1609
17.17 FRESENIUS SE & CO. KGAA 1610
17.17.1 COMPANY SNAPSHOT 1610
17.17.2 REVENUE ANALYSIS 1610
17.17.3 PRODUCT PORTFOLIO 1611
17.17.4 RECENT DEVELOPMENT 1612
17.18 GLENMARK PHARMACEUTICALS LTD. 1613
17.18.1 COMPANY SNAPSHOT 1613
17.18.2 REVENUE ANALYSIS 1614
17.18.3 PRODUCT PORTFOLIO 1614
17.18.4 RECENT DEVELOPMENTS 1617
17.19 HIKMA PHARMACEUTICALS PLC 1618
17.19.1 COMPANY SNAPSHOT 1618
17.19.2 REVENUE ANALYSIS 1618
17.19.3 PRODUCT PORTFOLIO 1619
17.19.4 RECENT DEVELOPMENTS 1620
17.20 INTAS PHARMACEUTICALS LTD. 1622
17.20.1 COMPANY SNAPSHOT 1622
17.20.2 PRODUCT PORTFOLIO 1622
17.20.3 RECENT DEVELOPMENTS 1626
17.21 JUBILANT GENERICS LIMITED (SUBSIDIARY OF JUBILANT PHARMA COMPANY) 1628
17.21.1 COMPANY SNAPSHOT 1628
17.21.2 PRODUCT PORTFOLIO 1628
17.21.3 RECENT DEVELOPMENTS 1630
17.22 LUPIN 1631
17.22.1 COMPANY SNAPSHOT 1631
17.22.2 REVENUE ANALYSIS 1631
17.22.3 PRODUCT PORTFOLIO 1632
17.22.4 RECENT DEVELOPMENTS 1636
17.23 MANKIND PHARMA LIMITED 1639
17.23.1 COMPANY SNAPSHOT 1639
17.23.2 REVENUE ANALYSIS 1640
17.23.3 PRODUCT PORTFOLIO 1640
17.23.4 RECENT DEVELOPMENTS 1644
17.24 NATCO PHARMA LIMITED 1645
17.24.1 COMPANY SNAPSHOT 1645
17.24.2 REVENUE ANALYSIS 1645
17.24.3 PRODUCT PORTFOLIO 1646
17.24.4 RECENT DEVELOPMENTS 1648
17.25 NEULAND LABORATORIES LTD. 1649
17.25.1 COMPANY SNAPSHOT 1649
17.25.2 REVENUE ANALYSIS 1649
17.25.3 PRODUCT PORTFOLIO 1650
17.25.4 RECENT DEVELOPMENT 1653
17.26 ORCHIDPHARMA LTD. 1654
17.26.1 COMPANY SNAPSHOT 1654
17.26.2 REVENUE ANALYSIS 1654
17.26.3 PRODUCT PORTFOLIO 1655
17.26.4 RECENT DEVELOPMENT 1656
17.27 PANACEA BIOTEC 1657
17.27.1 COMPANY SNAPSHOT 1657
17.27.2 REVENUE ANALYSIS 1657
17.27.3 PRODUCT PORTFOLIO 1658
17.27.4 RECENT DEVELOPMENT 1659
17.28 SAGENT 1660
17.28.1 COMPANY SNAPSHOT 1660
17.28.2 PRODUCT PORTFOLIO 1660
17.28.3 RECENT DEVELOPMENT 1661
17.29 STRIDES PHARMA SCIENCE LIMITED. 1662
17.29.1 COMPANY SNAPSHOT 1662
17.29.2 REVENUE ANALYSIS 1662
17.29.3 PRODUCT PORTFOLIO 1663
17.29.4 RECENT DEVELOPMENT 1666
17.30 TORRENT PHARMACEUTICALS LTD. 1667
17.30.1 COMPANY SNAPSHOT 1667
17.30.2 REVENUE ANALYSIS 1668
17.30.3 PRODUCT PORTFOLIO 1668
17.30.4 RECENT DEVELOPMENTS 1672
17.31 USV PRIVATE LIMITED. 1674
17.31.1 COMPANY SNAPSHOT 1674
17.31.2 SERVICE PORTFOLIO 1674
17.31.3 RECENT DEVELOPMENT 1682
17.32 WOCKHARDT LIMITED 1683
17.32.1 COMPANY SNAPSHOT 1683
17.32.2 REVENUE ANALYSIS 1684
17.32.3 PRODUCT PORTFOLIO 1684
17.32.4 RECENT DEVELOPMENT 1687
17.33 MCKESSON CORPORATION 1688
17.33.1 COMPANY SNAPSHOT 1688
17.33.2 REVENUE ANALYSIS 1689
17.33.3 PRODUCT PORTFOLIO 1690
17.33.4 RECENT DEVELOPMENT 1690
17.34 CENCORA, INC. 1691
17.34.1 COMPANY SNAPSHOT 1691
17.34.2 REVENUE ANALYSIS 1692
17.34.3 PRODUCT PORTFOLIO 1692
17.34.4 RECENT DEVELOPMENT 1693
17.35 CARDINAL HEALTH 1694
17.35.1 COMPANY SNAPSHOT 1694
17.35.2 REVENUE ANALYSIS 1694
17.35.3 PRODUCT PORTFOLIO 1695
17.35.4 RECENT DEVELOPMENT 1695
17.36 ALVOGEN 1696
17.36.1 COMPANY SNAPSHOT 1696
17.36.2 SERVICE PORTFOLIO 1696
17.36.3 RECENT DEVELOPMENT 1696
18 QUESTIONNAIRE 1697
19 RELATED REPORTS 1700
?

Not Sure / Need Reassuring
- Confirm Content
  - Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
    
    Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
    
    Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
    
    Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
- Sample Pages
  - With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
    
    It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
    
    To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Check for Alternatives
  - Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
    
    To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
Prices / Formats / Delivery
- Prices
  - All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
    
    Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Discounts
  - As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
    
    Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
    
    To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Available Currencies
  - Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
    
    Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
    
    To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
- Licenses
  - License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
    
    If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
- Global Site License
  - The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
    
    It is important to note that this may exclude Parent Companies or Subsidiaries.
    
    If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
- Formats
  - The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
    
    If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
- Delivery
  - Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
    
    Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
    
    If a delay in delivery is expected you will be informed about it immediately.
- Shipping Charges
  - As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
    
    If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
Ordering
- By Credit Card
  - We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
    
    Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
    
    For more information on PayU please visit: https://www.payu.pl/en/about-us
- By Money Transfer
  - If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
    
    With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
Security
- Website security
  - We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
    
    Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
- Credit Card Security
  - We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
    
    PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.